Ono Pharmaceutical Co., Ltd. OPHLY
4.83 USD -0.02 (-0.41%)
Nov 3, 2026, 10:01 AM EST
4.83 Day range 4.83
4.07 52-week range 5.75
- YTD
- +6.15%
- 1 year
- +21.05%
- Market cap
- 6.81B
- EPS (ttm)
- 0.34
- P/E ratio
- 14.21
- YTD return
- +6.15%
- 1-year return
- +21.05%
- Volume
- 400
- Avg volume
- 49.80K
- Open
- 4.83
- Previous close
- 4.85
- Day's range
- 4.83 – 4.83
- 52-week range
- 4.07 – 5.75
- Earnings date
- Nov 2, 2026
2Y +0.55 (+12.82%)
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 0.08198.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | 0.08198 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.07164 | 0.1076 | +0.04 | +50.20% |
| May 7, 2026 | Mar 31, 2026 | 0.0172 | 0.0037 | -0.01 | -78.49% |
| Feb 1, 2026 | Dec 31, 2025 | 0.09634 | 0.1315 | +0.04 | +36.50% |
| Oct 28, 2025 | Sep 30, 2025 | 0.08968 | 0.1079 | +0.02 | +20.32% |
| Jul 28, 2025 | Jun 30, 2025 | 0.1134 | 0.0865 | -0.03 | -23.72% |
News
Ono Pharma Announces Results From Five Phase 2 Clinical Studies of ONO-1110, an Endocannabinoid Modulator 
Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases 
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting 
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology 
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL 
Ono Pharmaceutical Co., Ltd. (OPHLY) Presents at 44th Annual J.P. 
Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 FY2025 Earnings Call Transcript 
Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 2024 Earnings Call Transcript 
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion 
ONO to buy Deciphera Pharmaceuticals at a huge premium
Your note
Sign in to keep a note on OPHLY — it syncs with the Stock Master app.